Reaction

Optic Neuropathy reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,070 reports · 47 co-occurring drugs

As of the last recalculation, Optic Neuropathy appears in 2,070 FAERS reports alongside 47 co-occurring drug terms. The strongest observed disproportionality signal is LINEZOLID (PRR 89.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Linezolid	234	89.0	89.7
Pyrazinamide	55	60.5	60.8
Rifampicin	46	46.7	46.9
Rifampin	62	44.0	44.2
Moxifloxacin	41	29.8	29.9
Isoniazid	47	29.8	29.9
Amiodarone Hydrochloride	31	28.2	28.3
Moxifloxacin Hydrochloride	42	21.2	21.3
Entecavir	21	18.3	18.3
Amikacin	28	16.7	16.7
Posaconazole Delayed-Release	16	14.8	14.8
Clarithromycin	48	14.4	14.4
Trimethoprim	14	12.0	12.0
Brinzolamide	10	11.6	11.6
Atovaquone	9	11.3	11.3
Posaconazole	17	10.6	10.6
Dorzolamide Hydrochloride And Timolol Maleate	8	10.2	10.2
Travoprost	8	9.3	9.3
Tacrolimus Ointment 0.1%	109	9.2	9.2
Tacrolimus Extended-Release Capsules	109	9.2	9.2
Temozolomide	19	9.1	9.1
Tacrolimus	133	9.1	9.1
Levofloxacin	52	8.9	8.9
Levofloxacin In 5% Dextrose	52	8.9	8.9
Telmisartan	15	8.5	8.5
Amitriptyline Hydrochloride	14	8.1	8.1
Metronidazole Topical	37	7.9	7.9
Nebivolol	12	7.6	7.6
Leucovorin Calcium	14	7.4	7.4
Brimonidine Tartrate	13	7.4	7.4
Mycophenilic Acid	15	7.3	7.3
Valacyclovir	28	6.8	6.8
Sirolimus	9	6.7	6.7
Dronedarone	6	5.9	5.9
Crizotinib	7	5.6	5.6
Daptomycin	5	5.5	5.5
Pemetrexed Disodium	17	4.5	4.5
Gemcitabine	15	3.8	3.9
Ranibizumab	10	3.8	3.8
Bortezomib	33	3.8	3.8
Ravulizumab	5	3.7	3.7
Ruxolitinib	26	3.7	3.7
Ribavirin	23	3.6	3.6
Vigabatrin	5	3.5	3.5
Aflibercept	9	2.9	2.9
Ipilimumab	12	2.8	2.8
Diroximel Fumarate	3	2.5	2.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.